Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (321-330 of 398) with videos related to

Pageof 40
Sort By:
The EMBO Journal|August 15, 1994
Molecular characterization of a family of ligands for eph-related tyrosine kinase receptorsM P Beckmann, D P Cerretti, P Baum, et al.
Pancreas|April 15, 2015
Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasmDaniel Kaemmerer, Ralph M Wirtz, Elke K Fischer, et al.
European Journal of Pediatrics|May 1, 1987
131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experienceD Schwabe, S Sahm, V Gerein, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
Revista Espanola De Medicina Nuclear|March 12, 1999
[Radioimmunoscintigraphy of colorectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results]J Oliva, G Pimentel, R Peralta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2016
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyRichard P Baum, Harshad R Kulkarni, Christiane Schuchardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1996
Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECTI A Adamietz, R P Baum, F Schemman, et al.
Theranostics|December 8, 2025
Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH studyGiulia Santo, Margarida Rodrigues, Diana Paez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1996
Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulationM Eisenhut, W D Lehmann, W Becker, et al.
Oncogene|November 1, 1994
LERK-2, a binding protein for the receptor-tyrosine kinase ELK, is evolutionarily conserved and expressed in a developmentally regulated patternF A Fletcher, M K Carpenter, H Shilling, et al.
Pageof 40

Showing results (321-330 of 398) with videos related to

Sort By:
Pageof 40
The EMBO Journal|August 15, 1994
Molecular characterization of a family of ligands for eph-related tyrosine kinase receptorsM P Beckmann, D P Cerretti, P Baum, et al.
Pancreas|April 15, 2015
Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasmDaniel Kaemmerer, Ralph M Wirtz, Elke K Fischer, et al.
European Journal of Pediatrics|May 1, 1987
131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experienceD Schwabe, S Sahm, V Gerein, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2015
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CTTheodosia Maina, Hendrik Bergsma, Harshad R Kulkarni, et al.
Revista Espanola De Medicina Nuclear|March 12, 1999
[Radioimmunoscintigraphy of colorectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results]J Oliva, G Pimentel, R Peralta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2016
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and EfficacyRichard P Baum, Harshad R Kulkarni, Christiane Schuchardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1996
Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECTI A Adamietz, R P Baum, F Schemman, et al.
Theranostics|December 8, 2025
Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH studyGiulia Santo, Margarida Rodrigues, Diana Paez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1996
Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulationM Eisenhut, W D Lehmann, W Becker, et al.
Oncogene|November 1, 1994
LERK-2, a binding protein for the receptor-tyrosine kinase ELK, is evolutionarily conserved and expressed in a developmentally regulated patternF A Fletcher, M K Carpenter, H Shilling, et al.
Pageof 40